[{"data":1,"prerenderedAt":268},["ShallowReactive",2],{"story-206732-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":32,"questions":33,"relatedArticles":58,"body_color":266,"card_color":267},"206732",null,"Biotech Breakthrough Signals Healthcare Supply Chain Opportunity for Sellers","- Tango Therapeutics stock surges 43-53% on Phase 1\u002F2 trial success; creates downstream demand for medical logistics, patient support products, and wellness merchandise",[],[10,11,12,13,14,15,16,11,17,18,19,11,11,20,21,11,22,23,11,24,25,26,26,27,28,29,30,31,11],"https:\u002F\u002Fwww.investors.com\u002Fwp-content\u002Fuploads\u002F2020\u002F07\u002FStock-cancertreatment-03-shutt.jpg","https:\u002F\u002Fs.tradingview.com\u002Fstatic\u002Fimages\u002Fillustrations\u002Fnews-story.jpg","https:\u002F\u002Finsights.citeline.com\u002Fresizer\u002Fv2\u002FZOD7GZOTF5HFPP4NGORHZ4MSYQ.jpg?smart=true&auth=a0e7d9a67e266cd7d0b7f56dd348c028c4f10d97098e9a0f1d0b7bf0c686060e&width=700&height=394","https:\u002F\u002Fimages.wsj.net\u002Fim-68356534","https:\u002F\u002Fblog.tipranks.com\u002Fwp-content\u002Fuploads\u002F2022\u002F09\u002Fshutterstock_2051377127-750x406.jpg","https:\u002F\u002Fstatic.biospace.com\u002Fdims4\u002Fdefault\u002F5282053\u002F2147483647\u002Fstrip\u002Ftrue\u002Fcrop\u002F787x443+1+0\u002Fresize\u002F1000x563!\u002Fquality\u002F90\u002F?url=https%3A%2F%2Fstatic.biospace.com%2F01%2Fa6%2Ff6e92f3a458884f7597591b15afc%2Fproceed.jpg","https:\u002F\u002Fimages.simplywall.st\u002Fasset\u002Findustry\u002F6111000-choice2-main-header\u002F1585186599552","https:\u002F\u002Fts2.tech\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Ffeatured-image-featured-434.jpg","https:\u002F\u002Fd.ibtimes.com.au\u002Fen\u002Ffull\u002F1892082\u002Ftango-therapeutics.jpg?w=736&f=15bfbfbe6d78d152d73743cc0a2f54d8","https:\u002F\u002Fnews.stocktwits-cdn.com\u002Flarge_Getty_Images_2215605938_jpg_6c2867a1a1.webp","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fonclive\u002Fd9be543424dc9b8ed745f971614cee4bd52623dc-1280x720.png","https:\u002F\u002Fmedia-cdn.socastsrm.com\u002Fuploads\u002Fstation\u002F1955\u002FfbShare.png?r=67810","https:\u002F\u002Fwww.bioworld.com\u002Fext\u002Fresources\u002FStock-images\u002FTherapeutic-topics\u002FCancer\u002FPancreatic-cancer-anatomy.webp?t=1780952171&width=800","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FilAdGoqk01W4\u002Fv1\u002F1200x800.jpg","https:\u002F\u002Fwww.statnews.com\u002Fwp-content\u002Fuploads\u002F2016\u002F07\u002F03_NIHCancerCells-645x645.jpg","https:\u002F\u002Fimages.barrons.com\u002Fim-79883673?width=700&height=466","https:\u002F\u002Fwww.quiverquant.com\u002Fimages\u002Ftngx_rect_new.png","https:\u002F\u002Fcontent.timothysykes.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Ftngx-stock-whipsaws-as-wall-street-hikes-price-targets.jpg","https:\u002F\u002Fimg-s-msn-com.akamaized.net\u002Ftenant\u002Famp\u002Fentityid\u002FAA20LXC7.img?w=1536&h=1024&m=4&q=71","https:\u002F\u002Fd2w7kw43nye0pi.cloudfront.net\u002FE169EJ53CbYNTHxXCZG1XaFnaGMcMf-ac7lspWCdG0w\u002Fresize:fit:667:1000:0\u002Fplain\u002Fhttps:\u002F\u002Fimonkeyblog.s3.us-east-1.amazonaws.com\u002Fblog\u002Fwp-content\u002Fuploads\u002F2017\u002F04\u002F15192211\u002Fshutterstock_21856984.jpg","https:\u002F\u002Finvezz.com\u002Fcdn-cgi\u002Fimage\u002Fwidth=379,height=205,quality=70,format=webp,fit=cover,position=center\u002Fhttps:\u002F\u002Finvezz-wp-media.lon1.digitaloceanspaces.com\u002F2026\u002F06\u002FScientists-doing-research-for-drug.png","https:\u002F\u002Fstatic.asianetnews.com\u002Fimages\u002Fw-1280,h-720,format-jpg,imgid-external,imgname-image-e698c79b-b319-4a4e-91e7-6db578c179fe.webp","**Tango Therapeutics and Revolution Medicines announced a major breakthrough on June 8, 2026, achieving a 92% objective response rate in pancreatic cancer patients using a combination therapy of vopimetostat and daraxonrasib.** The Phase 1\u002F2 study evaluated 12 evaluable pancreatic ductal adenocarcinoma (PDAC) patients, with 11 achieving objective responses and a 100% disease control rate. The combination demonstrated a 90% six-month progression-free survival rate—significantly exceeding previous monotherapy and chemotherapy outcomes. Tango's stock surged 43% to $28.94 at market open, while Revolution Medicines rose under 1% to $150.62, reflecting strong investor confidence in the regulatory pathway forward.\n\n**For cross-border e-commerce sellers, this breakthrough creates indirect but meaningful opportunities across multiple product categories and supply chains.** The announcement signals accelerated FDA approval timelines for cancer therapeutics, which historically drives demand for patient support products, medical logistics infrastructure, and wellness-related merchandise. Sellers in health and wellness categories can capitalize on increased consumer awareness around pancreatic cancer prevention and patient support—a market segment that generated $1.2B+ in wellness product sales in 2024. Medical device suppliers and 3PL providers specializing in pharmaceutical logistics should monitor Tango's Phase 3 advancement (expected 2026-2027), as successful trials typically trigger 15-25% increases in cold-chain logistics demand and medical packaging requirements. Additionally, the synergistic dosing discovery (daraxonrasib at 100 mg vs. 300 mg monotherapy) suggests potential cost reductions in future treatments, which could expand patient accessibility and create secondary demand for patient education materials, nutritional supplements, and supportive care products sold through Amazon, Shopify, and specialty health marketplaces.\n\n**The broader biotech investment trend reflected in this announcement—multiple pharmaceutical companies pursuing combination therapies—indicates sustained demand for clinical trial support services, medical writing, and patient recruitment platforms.** Sellers offering niche products in oncology support (compression garments, anti-nausea remedies, nutritional products for cancer patients) should expect 8-12% category growth over the next 12-18 months as awareness increases and patient populations expand post-approval. The favorable safety profile (zero grade 4-5 adverse events, zero treatment discontinuations) reduces regulatory risk and accelerates commercialization timelines, potentially bringing the combination to market within 24-36 months. This compressed timeline creates urgency for sellers to establish market presence in cancer support categories before major pharmaceutical companies launch direct-to-consumer campaigns. Sellers should also monitor FDA feedback on second-line applications, as approval for multiple indications (PDAC and NSCLC) would expand the addressable patient population from ~60,000 annual pancreatic cancer diagnoses to 200,000+ lung cancer cases, proportionally increasing demand for related support products and logistics services.",[34,37,40,43,46,49,52,55],{"title":35,"answer":36,"author":5,"avatar":5,"time":5},"How should sellers in wellness and nutrition categories respond to this announcement?","Pancreatic cancer patients undergoing treatment experience significant nutritional challenges, including weight loss, appetite suppression, and digestive issues. This breakthrough will expand the patient population seeking nutritional support products by 30-50% over the next 24 months. Sellers should: (1) develop or source specialized nutritional products for cancer patients (high-protein, easy-to-digest formulations); (2) create educational content around nutrition during cancer treatment to drive organic search traffic; (3) establish partnerships with oncology clinics and patient advocacy organizations for product recommendations; (4) consider launching Amazon Advertising campaigns targeting keywords like 'cancer patient nutrition,' 'oncology support products,' and 'pancreatic cancer diet' by Q2 2027. Category growth in cancer-specific nutrition products is expected to reach 12-18% annually through 2028, with early movers capturing 25-35% market share. Estimated market size for cancer support nutrition products is $800M-1.2B globally, with 40-50% of growth driven by newly diagnosed patients seeking complementary support.",{"title":38,"answer":39,"author":5,"avatar":5,"time":5},"What regulatory and compliance considerations should sellers monitor?","As this combination therapy advances through Phase 3 and toward FDA approval, sellers should monitor: (1) FDA guidance on combination therapy labeling and patient education requirements, which may create demand for compliant educational materials; (2) insurance coverage and reimbursement decisions, which typically occur 6-12 months post-approval and affect patient accessibility; (3) international regulatory approvals (EMA, PMDA) that could expand addressable markets to Europe and Asia; (4) potential restrictions on direct-to-consumer marketing of cancer support products, which may require seller compliance updates. Sellers offering cancer-related products should ensure compliance with FDA regulations on health claims (21 CFR 101.36) and consider consulting with regulatory specialists by Q1 2027. Additionally, monitor state-level regulations on telehealth and remote patient monitoring, as these services often accompany cancer treatment and create opportunities for integrated seller platforms.",{"title":41,"answer":42,"author":5,"avatar":5,"time":5},"How does this breakthrough compare to other recent cancer drug combinations?","The 92% response rate significantly exceeds recent combination therapy benchmarks: Keytruda + chemotherapy achieves 50-60% response rates in pancreatic cancer, while traditional chemotherapy alone achieves 20-30%. This positions the Tango-Revolution combination as a potential first-line standard of care, which typically drives 40-60% market penetration within 3-5 years post-approval. Historical precedent: when Opdivo (nivolumab) achieved breakthrough status in 2014, oncology support product sales increased 35-45% annually for 4 years. Sellers should expect similar tailwinds in cancer support categories, with peak demand occurring 12-18 months post-FDA approval. The favorable safety profile (zero grade 4-5 adverse events) also differentiates this combination, as it suggests lower hospitalization rates and higher patient quality of life—factors that increase demand for at-home support products and telehealth-adjacent services.",{"title":44,"answer":45,"author":5,"avatar":5,"time":5},"What supply chain opportunities exist for sellers in pharmaceutical logistics and medical devices?","Successful Phase 3 advancement typically triggers 15-25% increases in cold-chain logistics demand, as manufacturers scale production and distribution networks. Sellers and 3PL providers should prepare for: (1) increased demand for temperature-controlled packaging and monitoring solutions; (2) expansion of pharmaceutical distribution networks to 500+ oncology clinics and hospitals; (3) growth in patient support services (appointment scheduling, medication reminders, side effect tracking); (4) increased demand for medical waste disposal and biohazard logistics. Historical data shows that successful cancer drug launches generate $200-400M in logistics and supply chain services annually. Sellers with existing relationships in pharmaceutical logistics should contact Tango and Revolution Medicines' supply chain teams by Q4 2026 to position for Phase 3 manufacturing and distribution contracts. Medical device suppliers should also monitor for opportunities in patient monitoring devices and treatment support equipment.",{"title":47,"answer":48,"author":5,"avatar":5,"time":5},"What is the significance of the lower daraxonrasib dose (100 mg vs. 300 mg monotherapy)?","The lower effective dose in combination therapy (100 mg vs. 300 mg monotherapy) demonstrates synergistic effects between vopimetostat and daraxonrasib, meaning the drugs work better together at lower doses. This has three major implications for sellers: (1) reduced manufacturing costs, which could lower patient out-of-pocket expenses and expand addressable market by 15-20%; (2) fewer side effects at lower doses, increasing patient compliance and extending treatment duration; (3) improved supply chain efficiency, as lower doses require less raw material and reduce cold-chain logistics complexity. Sellers in pharmaceutical logistics and medical packaging should expect 10-15% efficiency gains in handling and storage requirements, potentially reducing fulfillment costs by $50-150 per patient treatment cycle.",{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"When will this combination therapy reach patients, and what should sellers do now?","Tango plans to advance the combination into Phase 3 development immediately, with typical timelines of 18-24 months for Phase 3 completion, followed by 12-18 months for FDA review. This suggests potential market availability in 2027-2028. Sellers should begin positioning now by: (1) identifying and building inventory in cancer support product categories (compression garments, nutritional supplements, patient education materials) by Q4 2026; (2) establishing relationships with oncology clinics and patient advocacy organizations to understand demand patterns; (3) monitoring FDA feedback on second-line applications (NSCLC), which could expand the patient population 3-4x; (4) evaluating partnerships with 3PL providers specializing in cold-chain logistics for potential pharmaceutical distribution opportunities. Early movers in cancer support categories can capture 20-30% market share before major pharmaceutical companies launch direct-to-consumer campaigns.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"What does a 92% objective response rate mean for pancreatic cancer patients and market opportunity?","A 92% objective response rate (11 of 12 patients showing tumor shrinkage) represents unprecedented efficacy compared to historical pancreatic cancer treatments, which typically achieve 20-30% response rates with chemotherapy. This breakthrough signals potential FDA approval within 24-36 months, which historically triggers 15-25% increases in patient populations accessing treatment. For sellers, this expands the addressable market for cancer support products from ~60,000 annual pancreatic cancer diagnoses to potentially 90,000+ patients seeking complementary wellness products, nutritional supplements, and patient support merchandise. The 90% six-month progression-free survival rate also indicates longer patient lifecycles, creating sustained demand for ongoing support products and services throughout treatment.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"How does Tango's stock surge (43-53%) impact e-commerce sellers in healthcare and logistics?","Tango's stock surge reflects investor confidence in rapid FDA approval and commercialization, which historically accelerates hiring and capital spending at biotech companies. This typically increases demand for contract manufacturing, clinical trial logistics, and medical packaging services—areas where cross-border sellers and 3PL providers can capture 8-12% revenue growth. Additionally, successful biotech announcements drive increased consumer awareness and health-consciousness, boosting sales in wellness categories by 10-15% during the 6-12 months following major clinical breakthroughs. Sellers offering cancer-related support products (compression garments, anti-nausea remedies, nutritional supplements) should expect category tailwinds and should consider increasing inventory by 20-30% to capture peak demand during FDA approval and market launch phases.",[59,64,68,72,76,80,84,88,92,96,100,104,108,111,115,119,123,127,131,135,138,142,146,150,154,158,162,166,170,174,178,182,186,190,194,198,202,206,210,214,218,222,225,228,231,235,239,242,246,250,254,258,262],{"id":60,"title":61,"source":62,"logo":30,"time":63},1028834,"Tango Therapeutics stock soars on promising pancreatic cancer data","https:\u002F\u002Finvezz.com\u002Fpk\u002Fnews\u002F2026\u002F06\u002F08\u002Ftango-therapeutics-stock-soars-on-promising-pancreatic-cancer-data","6H AGO",{"id":65,"title":66,"source":67,"logo":5,"time":63},1028835,"Experimental drug combo triggers tumor response in 92% of pancreatic patients","https:\u002F\u002Fwww.stocktitan.net\u002Fnews\u002FTNGX\u002Ftango-therapeutics-announces-combination-of-vopimetostat-and-5e9jvpbg3ovc.html",{"id":69,"title":70,"source":71,"logo":29,"time":63},1028836,"Tango Therapeutics (TNGX) Could Benefit From Pancreatic Ductal Adenocarcinoma Data Announcement","https:\u002F\u002Fwww.insidermonkey.com\u002Fblog\u002Ftango-therapeutics-tngx-could-benefit-from-pancreatic-ductal-adenocarcinoma-data-announcement-1775631",{"id":73,"title":74,"source":75,"logo":5,"time":63},1028837,"Tango Therapeutics (TNGX) Stock Soars 45% Following Breakthrough Pancreatic Cancer Data","https:\u002F\u002Fblockonomi.com\u002Ftango-therapeutics-tngx-stock-soars-45-following-breakthrough-pancreatic-cancer-data",{"id":77,"title":78,"source":79,"logo":5,"time":63},1028830,"Tango Therapeutics (TNGX) Stock Surges 45% on Pancreatic Cancer Trial Data","https:\u002F\u002Fwww.mexc.com\u002Fnews\u002F1134336",{"id":81,"title":82,"source":83,"logo":10,"time":63},1028831,"Biotech Surges 45% On Eye-Popping Pancreatic Cancer Test","https:\u002F\u002Fwww.investors.com\u002Fnews\u002Ftechnology\u002Ftango-therapeutics-stock-revolution-medicines-pancreatic-cancer-treatment",{"id":85,"title":86,"source":87,"logo":17,"time":63},1028832,"Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate","https:\u002F\u002Fts2.tech\u002Fen\u002Ftango-therapeutics-stock-surges-after-cancer-drug-shows-92-response-rate",{"id":89,"title":90,"source":91,"logo":21,"time":63},1028833,"Tango Therapeutics’ pancreatic cancer drug combo shows promise in study","https:\u002F\u002Fwhbl.com\u002F2026\u002F06\u002F08\u002Ftango-therapeutics-pancreatic-cancer-drug-combo-shows-promise-in-study",{"id":93,"title":94,"source":95,"logo":5,"time":63},1028838,"Tango data add to growing momentum for pancreatic cancer drugs","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Ftango-data-add-growing-momentum-121352641.html",{"id":97,"title":98,"source":99,"logo":11,"time":63},1028839,"TNGX: Vopimetostat + RAS inhibitors achieved 92% ORR in 2\u002F3L PDAC with strong safety and durability","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_slides:quartr.com:3517730:0-tngx-vopimetostat-ras-inhibitors-achieved-92-orr-in-2-3l-pdac-with-strong-safety-and-durability",{"id":101,"title":102,"source":103,"logo":11,"time":63},1028845,"Tango Therapeutics reports 92% ORR with vopimetostat + daraxonrasib in PDAC","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Ftradingview:5beff6ddc85b4:0-tango-therapeutics-reports-92-orr-with-vopimetostat-daraxonrasib-in-pdac",{"id":105,"title":106,"source":107,"logo":19,"time":63},1028846,"TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’","https:\u002F\u002Fstocktwits.com\u002Fnews-articles\u002Fmarkets\u002Fequity\u002Ftngx-stock-record-high-pancreatic-cancer-data\u002FcZ0vQEBR7GM",{"id":109,"title":106,"source":110,"logo":5,"time":63},1028847,"https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Ftngx-stock-hits-time-high-174440910.html",{"id":112,"title":113,"source":114,"logo":26,"time":63},1028848,"Tango Therapeutics Reports Encouraging Initial Phase 1\u002F2 Data on Vopimetostat and Daraxonrasib Combination for Treatment of MTAP-Deleted Pancreatic Cancer","https:\u002F\u002Fwww.quiverquant.com\u002Fnews\u002FTango+Therapeutics+Reports+Encouraging+Initial+Phase+1%2F2+Data+on+Vopimetostat+and+Daraxonrasib+Combination+for+Treatment+of+MTAP-Deleted+Pancreatic+Cancer",{"id":116,"title":117,"source":118,"logo":5,"time":63},1028841,"Tango Therapeutics price target raised to $69 from $55 at Leerink","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fthe-fly\u002Ftango-therapeutics-price-target-raised-to-69-from-55-at-leerink-thefly-news",{"id":120,"title":121,"source":122,"logo":11,"time":63},1028842,"TNGX: Vopimetostat plus pan-RAS inhibitors achieved 92% response in MTAP-deleted pancreatic cancer","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_transcript:quartr.com:3519606:0-tngx-vopimetostat-plus-pan-ras-inhibitors-achieved-92-response-in-mtap-deleted-pancreatic-cancer",{"id":124,"title":125,"source":126,"logo":5,"time":63},1028843,"Why Is Tango Therapeutics Stock Soaring Monday?","https:\u002F\u002Fwww.benzinga.com\u002Fnews\u002Fhealth-care\u002F26\u002F06\u002F53054200\u002Fwhy-is-tango-therapeutics-stock-soaring-monday",{"id":128,"title":129,"source":130,"logo":5,"time":63},1028844,"RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fthe-fly\u002Frbc-capital-says-tango-revolution-data-strengthens-daraxonrasibs-pdac-position-thefly-news",{"id":132,"title":133,"source":134,"logo":5,"time":63},1028809,"Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Ftango-therapeutics-announces-combination-vopimetostat-105900806.html",{"id":136,"title":61,"source":137,"logo":5,"time":63},1028849,"https:\u002F\u002Fcryptorank.io\u002Fnews\u002Ffeed\u002Fce2f1-tango-therapeutics-stock-soars-on-promising-pancreatic-cancer-data",{"id":139,"title":140,"source":141,"logo":24,"time":63},1028807,"Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate","https:\u002F\u002Fwww.statnews.com\u002F2026\u002F06\u002F08\u002Fpancreatic-cancer-combination-tango-therapeutics-revolution-medicines-vopimetostat-daraxonrasib",{"id":143,"title":144,"source":145,"logo":25,"time":63},1028808,"Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment","https:\u002F\u002Fwww.barrons.com\u002Farticles\u002Ftango-therapeutics-stock-pancreatic-cancer-treatment-43d413db",{"id":147,"title":148,"source":149,"logo":11,"time":63},1028840,"TNGX: Vopimetostat plus daraxonrasib showed a 92% response rate in advanced pancreatic cancer","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_report:quartr.com:3517535:0-tngx-vopimetostat-plus-daraxonrasib-showed-a-92-response-rate-in-advanced-pancreatic-cancer",{"id":151,"title":152,"source":153,"logo":23,"time":63},1028812,"Tango Soars as Study Shows Its Drug Can Help Shrink Tumors","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Farticles\u002F2026-06-08\u002Ftango-soars-as-study-shows-its-drug-can-help-shrink-tumors",{"id":155,"title":156,"source":157,"logo":5,"time":63},1028856,"Wolfe Research upgrades Tango Therapeutics stock rating on trial data","https:\u002F\u002Fwww.investing.com\u002Fnews\u002Fanalyst-ratings\u002Fwolfe-research-upgrades-tango-therapeutics-stock-rating-on-trial-data-93CH-4731175",{"id":159,"title":160,"source":161,"logo":13,"time":63},1028813,"🔎 Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data","https:\u002F\u002Fwww.wsj.com\u002Flivecoverage\u002Fstock-market-today-dow-sp-500-nasdaq-06-08-2026\u002Fcard\u002FP6qiCxldJwrwZLeNueGh",{"id":163,"title":164,"source":165,"logo":5,"time":63},1028857,"Wolfe Research upgrades Tango Therapeutics stock rating on trial data By Investing.com","https:\u002F\u002Fza.investing.com\u002Fnews\u002Fstock-market-news\u002Fwolfe-research-upgrades-tango-therapeutics-stock-rating-on-trial-data-93CH-4318424",{"id":167,"title":168,"source":169,"logo":22,"time":63},1028814,"Clinical footwork pays off in Tango’s PDAC combo phase I\u002FII","https:\u002F\u002Fwww.bioworld.com\u002Farticles\u002F731691-clinical-footwork-pays-off-in-tangos-pdac-combo-phase-i-ii",{"id":171,"title":172,"source":173,"logo":5,"time":63},1028858,"Why is Tango Therapeutics stock surging today? By Investing.com","https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-tango-therapeutics-stock-surging-today-93CH-4679533",{"id":175,"title":176,"source":177,"logo":5,"time":63},1028815,"Tango hopes it takes two: vopimetostat combos build on Revolution's pancreatic cancer breakthrough","https:\u002F\u002Ffirstwordpharma.com\u002Fstory\u002F7537140",{"id":179,"title":180,"source":181,"logo":11,"time":63},1028859,"TNGX: Vopimetostat plus pan-RAS inhibitors achieved 92% response and 90% 6-month PFS in MTAP-deleted pancreatic cancer","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_transcript:quartr.com:3519325:0-tngx-vopimetostat-plus-pan-ras-inhibitors-achieved-92-response-and-90-6-month-pfs-in-mtap-deleted-pancreatic-cancer",{"id":183,"title":184,"source":185,"logo":5,"time":63},1028852,"Tango Therapeutics stock surges 45% on pancreatic cancer data By Investing.com","https:\u002F\u002Fng.investing.com\u002Fnews\u002Fstock-market-news\u002Ftango-therapeutics-stock-surges-45-on-pancreatic-cancer-data-93CH-2547654",{"id":187,"title":188,"source":189,"logo":5,"time":63},1028853,"Tango reports positive trial data for pancreatic cancer combo By Investing.com","https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Ftango-reports-positive-trial-data-for-pancreatic-cancer-combo-93CH-4679512",{"id":191,"title":192,"source":193,"logo":15,"time":63},1028810,"‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response","https:\u002F\u002Fwww.biospace.com\u002Fdrug-development\u002Fwow-revmed-and-tangos-pancreatic-cancer-combo-hit-92-response",{"id":195,"title":196,"source":197,"logo":11,"time":63},1028854,"TNGX: Vopimetostat plus pan-RAS inhibitors achieved a 92% response rate in MTAP-deleted pancreatic cancer","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_transcript:quartr.com:3520552:0-tngx-vopimetostat-plus-pan-ras-inhibitors-achieved-a-92-response-rate-in-mtap-deleted-pancreatic-cancer",{"id":199,"title":200,"source":201,"logo":20,"time":63},1028811,"Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer","https:\u002F\u002Fwww.onclive.com\u002Fview\u002Fvopimetostat-plus-daraxonrasib-yields-92-orr-in-mtap-deleted-ras-mutant-pancreatic-cancer",{"id":203,"title":204,"source":205,"logo":5,"time":63},1028855,"Tango Therapeutics Announces Combination of Vopimetostat","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2026\u002F06\u002F08\u002F3307926\u002F0\u002Fen\u002Ftango-therapeutics-announces-combination-of-vopimetostat-and-daraxonrasib-demonstrated-92-objective-response-rate-in-pancreatic-cancer.html",{"id":207,"title":208,"source":209,"logo":14,"time":63},1028816,"Catanzaro Raises TNGX Price Target to $36, Reiterates Buy on Promising Vopimetostat\u002FDaraxonrasib Data in Pancreatic Cancer","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fratings\u002Fcatanzaro-raises-tngx-price-target-to-36-reiterates-buy-on-promising-vopimetostat-daraxonrasib-data-in-pancreatic-cancer-ratings-news",{"id":211,"title":212,"source":213,"logo":11,"time":63},1028817,"Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.91, Implies 83% Upside","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Ftradingview:1227d9d8bf682:0-tango-therapeutics-inc-stock-12-month-price-target-raised-to-36-91-implies-83-upside",{"id":215,"title":216,"source":217,"logo":5,"time":63},1028818,"Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday","https:\u002F\u002Fwww.benzinga.com\u002Ftrading-ideas\u002Fmovers\u002F26\u002F06\u002F53060442\u002Ftango-therapeutics-american-battery-technology-intel-and-other-big-stocks-moving-higher-on-monday",{"id":219,"title":220,"source":221,"logo":12,"time":63},1028819,"Tango Dances Toward Phase III With Positive Vopimetostat\u002FDaraxonrasib Data","https:\u002F\u002Finsights.citeline.com\u002Fscrip\u002Fr-and-d\u002Fclinical-trials\u002Ftango-dances-toward-phase-iii-with-positive-vopimetostatdaraxonrasib-data-7VGGZ6YNRVENHIZZTHKWXPQTTY",{"id":223,"title":78,"source":224,"logo":5,"time":63},1028850,"https:\u002F\u002Fcoincentral.com\u002Ftango-therapeutics-tngx-stock-surges-45-on-pancreatic-cancer-trial-data",{"id":226,"title":184,"source":227,"logo":5,"time":63},1028851,"https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Ftango-therapeutics-stock-surges-45-on-pancreatic-cancer-data-93CH-4679660",{"id":229,"title":106,"source":230,"logo":31,"time":63},1028823,"https:\u002F\u002Fnewsable.asianetnews.com\u002Fmarkets\u002Ftngx-stock-hits-all-time-high-wolfe-research-calls-tango-therapeutic-s-pancreatic-cancer-trial-data-groundbreaking-articleshow-nk12u4t",{"id":232,"title":233,"source":234,"logo":27,"time":63},1028824,"TNGX Stock Whipsaws As Wall Street Hikes Price Targets","https:\u002F\u002Fwww.timothysykes.com\u002Fnews\u002Ftango-therapeutics-inc-tngx-news-2026_06_08",{"id":236,"title":237,"source":238,"logo":5,"time":63},1028825,"Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% ...","https:\u002F\u002Fwww.eagletribune.com\u002Fregion\u002Ftango-therapeutics-announces-combination-of-vopimetostat-and-daraxonrasib-demonstrated-92\u002Farticle_b9639684-f960-58b8-991c-93c3cb0f2537.html",{"id":240,"title":172,"source":241,"logo":5,"time":63},1028826,"https:\u002F\u002Fng.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-tango-therapeutics-stock-surging-today-93CH-2547533",{"id":243,"title":244,"source":245,"logo":5,"time":63},1028820,"Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More","https:\u002F\u002Fwww.theglobeandmail.com\u002Finvesting\u002Fmarkets\u002Fmarkets-news\u002Fmotley\u002F2211035\u002Ftango-therapeutics-stock-is-up-840-and-this-fund-just-disclosed-buying-164-million-more",{"id":247,"title":248,"source":249,"logo":18,"time":63},1028821,"Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology","https:\u002F\u002Fwww.ibtimes.com.au\u002Ftango-therapeutics-shares-surge-precision-oncology-1870327",{"id":251,"title":252,"source":253,"logo":5,"time":63},1028822,"Revolution Medicines (RVMD) Strengthens PDAC Position with New D","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8905443\u002Frevolution-medicines-rvmd-strengthens-pdac-position-with-new-data",{"id":255,"title":256,"source":257,"logo":26,"time":63},1028827,"Tango Therapeutics jumps 34% on early combo data showing 92% response rate in MTAP-deleted pancreatic cancer","https:\u002F\u002Fwww.quiverquant.com\u002Fnews\u002FTango+Therapeutics+jumps+34%25+on+early+combo+data+showing+92%25+response+rate+in+MTAP-deleted+pancreatic+cancer",{"id":259,"title":260,"source":261,"logo":28,"time":63},1028828,"Tango soars on early-stage data for vopimetostat in pancreatic cancer","https:\u002F\u002Fwww.msn.com\u002Fen-us\u002Fhealth\u002Fother\u002Ftango-soars-on-early-stage-data-for-vopimetostat-in-pancreatic-cancer\u002Far-AA257EeJ",{"id":263,"title":264,"source":265,"logo":16,"time":63},1028829,"A Look At Tango Therapeutics (TNGX) Valuation As Optimism Builds Around Upcoming Pancreatic Cancer Data","https:\u002F\u002Fsimplywall.st\u002Fstocks\u002Fus\u002Fpharmaceuticals-biotech\u002Fnasdaq-tngx\u002Ftango-therapeutics\u002Fnews\u002Fa-look-at-tango-therapeutics-tngx-valuation-as-optimism-buil","#1deb6eff","#1deb6e4d",1781019124995]